Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

The winners, Nathan Gates, Faith Apostolodes, and Kevin Helm have shared some insights as to what inspired their winning ...

Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.

The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...

Google just dropped 4 new Gemini 2.0-series models, with some designed for coding performance and complex prompts and the ...

This new nonaddictive alternative is the first of its kind that interrupts the pain signal before it reaches the brain.

Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ ...

It's ideal for everyday tasks and is available in Google AI Studio and Vertex AI. Gemini app ... and it comes in the form of Gemini 2.0 Flash-Lite. Even though titled 'Lite,' Google says that ...